Processa Pharmaceuticals Reports Preclinical Data For NGC-Iri; Delivers More Cancer-Killing SN-38 Molecules To Tumor Than Irinotecan And Onivyde; Studies Support Potential Benefit As An Improved Treatment With Fewer Side Effects
Portfolio Pulse from Benzinga Newsdesk
Processa Pharmaceuticals (NASDAQ: PCSA) reports positive preclinical data for its Next Generation irinotecan (NGC-Iri), showing it delivers more cancer-killing SN-38 molecules to tumors with fewer side effects compared to irinotecan and Onivyde. The studies suggest NGC-Iri could be a more effective and safer cancer treatment.
August 19, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Processa Pharmaceuticals announced positive preclinical data for NGC-Iri, indicating it delivers more cancer-killing SN-38 molecules to tumors with fewer side effects compared to irinotecan and Onivyde. This suggests NGC-Iri could be a more effective and safer cancer treatment.
The positive preclinical data for NGC-Iri suggests it could be a superior cancer treatment compared to existing options, which is likely to boost investor confidence and positively impact PCSA's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100